Navamedic Valuation

Is NAVA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of NAVA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: NAVA (NOK26.7) is trading below our estimate of fair value (NOK119.2)

Significantly Below Fair Value: NAVA is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for NAVA?

Key metric: As NAVA is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for NAVA. This is calculated by dividing NAVA's market cap by their current earnings.
What is NAVA's PE Ratio?
PE Ratio	24x
Earnings	NOK 19.62m
Market Cap	NOK 485.73m

NAVA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.1x
Enterprise Value/EBITDA	10.2x
PEG Ratio	0.8x

Price to Earnings Ratio vs Peers

How does NAVA's PE Ratio compare to its peers?

The above table shows the PE ratio for NAVA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	68.9x
VISTN Vistin Pharma	18.1x	n/a	NOK 1.1b
PHO Photocure	95x	94.2%	NOK 1.3b
AZT ArcticZymes Technologies	144.6x	73.8%	NOK 673.1m
539730 Fredun Pharmaceuticals	17.9x	n/a	₹3.2b
NAVA Navamedic	24x	29.6%	NOK 485.7m

Price-To-Earnings vs Peers: NAVA is good value based on its Price-To-Earnings Ratio (24x) compared to the peer average (68.9x).

Price to Earnings Ratio vs Industry

How does NAVA's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: NAVA is expensive based on its Price-To-Earnings Ratio (24x) compared to the European Pharmaceuticals industry average (21.1x).

Price to Earnings Ratio vs Fair Ratio

What is NAVA's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

NAVA PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	24x
Fair PE Ratio	12.5x

Price-To-Earnings vs Fair Ratio: NAVA is expensive based on its Price-To-Earnings Ratio (24x) compared to the estimated Fair Price-To-Earnings Ratio (12.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst NAVA forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	NOK 26.70	NOK 37.00 +38.6%	2.7%	NOK 38.00	NOK 36.00	n/a	2
Nov ’25	NOK 25.00	NOK 45.50 +82.0%	1.1%	NOK 46.00	NOK 45.00	n/a	2
Oct ’25	NOK 30.10	NOK 45.50 +51.2%	1.1%	NOK 46.00	NOK 45.00	n/a	2
Sep ’25	NOK 29.10	NOK 45.50 +56.4%	1.1%	NOK 46.00	NOK 45.00	n/a	2
Aug ’25	NOK 32.00	NOK 46.50 +45.3%	1.1%	NOK 47.00	NOK 46.00	n/a	2
Jul ’25	NOK 33.00	NOK 46.50 +40.9%	1.1%	NOK 47.00	NOK 46.00	n/a	2
Jun ’25	NOK 33.90	NOK 49.00 +44.5%	6.1%	NOK 52.00	NOK 46.00	n/a	2
May ’25	NOK 32.40	NOK 49.00 +51.2%	6.1%	NOK 52.00	NOK 46.00	n/a	2
Apr ’25	NOK 35.60	NOK 51.00 +43.3%	2.0%	NOK 52.00	NOK 50.00	n/a	2
Mar ’25	NOK 37.00	NOK 49.00 +32.4%	2.0%	NOK 50.00	NOK 48.00	n/a	2
Feb ’25	NOK 38.50	NOK 49.00 +27.3%	2.0%	NOK 50.00	NOK 48.00	n/a	2
Jan ’25	NOK 36.70	NOK 49.00 +33.5%	2.0%	NOK 50.00	NOK 48.00	n/a	2
Dec ’24	NOK 38.50	NOK 49.00 +27.3%	2.0%	NOK 50.00	NOK 48.00	n/a	2
Nov ’24	NOK 38.90	NOK 47.00 +20.8%	6.4%	NOK 50.00	NOK 44.00	NOK 25.00	2
Oct ’24	NOK 39.30	NOK 47.00 +19.6%	6.4%	NOK 50.00	NOK 44.00	NOK 30.10	2
Sep ’24	NOK 32.00	NOK 47.00 +46.9%	6.4%	NOK 50.00	NOK 44.00	NOK 29.10	2
Aug ’24	NOK 36.80	NOK 50.50 +37.2%	5.0%	NOK 53.00	NOK 48.00	NOK 32.00	2
Jul ’24	NOK 38.50	NOK 49.00 +27.3%	8.2%	NOK 53.00	NOK 45.00	NOK 33.00	2
Jun ’24	NOK 37.90	NOK 49.00 +29.3%	8.2%	NOK 53.00	NOK 45.00	NOK 33.90	2
May ’24	NOK 36.40	NOK 50.00 +37.4%	10.0%	NOK 55.00	NOK 45.00	NOK 32.40	2
Apr ’24	NOK 40.10	NOK 50.00 +24.7%	10.0%	NOK 55.00	NOK 45.00	NOK 35.60	2
Mar ’24	NOK 36.50	NOK 50.00 +37.0%	10.0%	NOK 55.00	NOK 45.00	NOK 37.00	2

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.